AssetMark Inc
HQL

AssetMark Inc’s abrdn Life Sciences Investors HQL Stock Holding History

AssetMark Inc’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.31K Hold
265
– – ﹤0.01% 2622
2025
Q4 		$4.45K Hold
265
– – ﹤0.01% 2504
2025
Q3 		$4.11K Hold
265
– – ﹤0.01% 2410
2025
Q2 		$3.4K Buy
+265
New +$3.27K ﹤0.01% 2256

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AssetMark Inc's HQL Position: Q1 2026 in Review

AssetMark Inc held its abrdn Life Sciences Investors (HQL) position steady in Q1 2026 at 265 shares worth $4.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

AssetMark Inc first reported a position in HQL in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.45K in Q4 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • AssetMark Inc held 265 shares of abrdn Life Sciences Investors worth $4.31K as of Q1 2026.
  • AssetMark Inc left its abrdn Life Sciences Investors share count unchanged in Q1 2026.
  • abrdn Life Sciences Investors made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #2622 holding.
  • AssetMark Inc first reported a position in abrdn Life Sciences Investors in Q2 2025 and has held it in 4 quarters since.
  • AssetMark Inc's abrdn Life Sciences Investors position peaked at $4.45K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.